Respiratory Syncytial Virus (RSV) viral protein translation inhibitors
Respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract infection (LRTI) in infants, young children (up to the age of 5) and adults above the age of 65.
A new strategy for the discovery of anti-viral drugs
Instead of directly targeting viral proteins, which are prone to high mutation rate, we are targeting the mechanisms by which viruses hijack the translation machinery, forcing cells to produce high amounts of the viral protein. This host-virus interaction represents a novel intervention point and a new strategy against multiple viruses.
Using our platform, we discovered and validated highly selective compounds that rescue infected cells from virus-mediated death with no effect on non-infected cells.
- High throughput screening using Anima’s proprietary platform
Two chemically diverse series identified
- Dose-response shown with activity at the nM levels in cell-based assays
- Compounds rescue infected cells from virus-mediated death
- Compounds reduce viral load that is correlated with an increase in cell viability
- Compounds demonstrate selectivity toward RSV infected cells
- Do not affect global translation
- Safe to non-infected cells
- Compounds optimization
Mode of action disruptive to viral organization